Core Insights - TransCode Therapeutics has initiated a Phase 1 clinical trial for TTX-MC138, an antisense oligonucleotide aimed at treating metastatic cancer by inhibiting microRNA-10b, a known driver of metastasis [1][2] - The trial has successfully dosed the first two patients, marking a significant milestone in the development of TTX-MC138 [2] - TTX-MC138 is positioned as a first-in-class therapeutic candidate with the potential to improve outcomes across various cancers, including breast, pancreatic, ovarian, colon, and lung cancers [2] Trial Details - The Phase 1 clinical trial is a multicenter, open-label, dose-escalation and dose-expansion study designed to evaluate the safety and tolerability of TTX-MC138 in patients with metastatic solid cancers [3] - The trial consists of an initial dose-escalation phase followed by a dose-expansion phase, with the primary objective of assessing safety and tolerability [3] - While not an endpoint, the trial may provide early evidence of clinical activity for TTX-MC138 [3] Company Overview - TransCode Therapeutics is a clinical-stage oncology company focused on treating metastatic disease through RNA therapeutics, utilizing its proprietary TTX nanoparticle platform [5] - The company aims to address the challenges of RNA delivery and unlock therapeutic access to novel genetic targets relevant to various cancers [5] - TTX-MC138 specifically targets tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis [5]
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate